文章摘要

术前血小板/ 淋巴细胞比值与肝癌预后的关系

作者: 1苏子剑, 2翟军伟, 1潘群雄, 1王聪仁, 1张剑华, 1柯少迎, 3张胜利
1 福建医科大学附属泉州第一医院 肝胆外科，福建 泉州 362000
2 山东省滕州市中心人民医院 外科，山东 滕州 277500
3 福建中医药大学管理学院，福建 福州 350122
通讯: 潘群雄 Email: zijiansue@126.com
DOI: 10.3978/.10.3978/j.issn.1005-6947.2016.01.003
基金: 福建省自然科学基金资助项目, 2014J01435 福建省泉州市科技计划资助项目, 2013Z58

摘要

目的：探讨术前血小板/ 淋巴细胞比值（PLR）与肝癌预后的关系。方法：回顾性分析行手术治疗的256 例肝癌患者的临床资料。根据患者术前PLR 水平，绘制PLR 诊断肿瘤复发的受试者工作特征（ROC）曲线，确定PLR 界值，分析术前外周血PLR 水平分与患者临床病理因素及预后的关系。结果：PLR 诊断肿瘤ROC 曲线下面积为0.625（95% CI=0.544~0.706），灵敏度为0.53，特异度为0.70，界值为131.81。患者术前外周血PLR 水平与术前血清白蛋白、Child-Pugh 分级、是否伴有腹水、血管侵犯、TNM 分期等临床病理因素有关（均P<0.05）。Cox 风险模型分析显示，TNM 分期（HR=1.441，95% CI=1.721~2.635，P<0.001）、PLR（HR=1.737，95% CI=1.317~2.291，P<0.001）为肝癌预后的独立影响因素，而PLR（HR=1.893，95% CI=1.434~2.497，P<0.001）为肝癌复发的独立影响因素。生存分析显示，低PLR 患者术后1、3、5 年无瘤生存率（81.2%、53.3%、29.6%）明显高于PLR 患者（62.4%、30.4%、11.6%）。结论：术前PLR 可以作为肝癌患者的预后指标，高PLR 水平患者术后复发率高、预后差。
关键词： 癌，肝细胞 血小板/ 淋巴细胞比值 预后

Relationship between platelet-to-lymphocyte ratio and prognosis in patients with hepatocellular carcinoma

Authors: 1SU Zijian, 2QU Junwei, 1PAN Qunxiong, 1WANG Congren, 1ZHANG Jianhua, 1KE Shaoying, 3ZHANG Shengli
1 Department of Hepatobiliary Surgery, Affiliated Quanzhou First Hospital, Fujian Medical University, Quanzhou, Fujian 362000, China
2 Department of Surgery, Tengzhou People Hospital, Tengzhou, Shandong 277500, China
3 School of Management, Fujian University of Chinese Medicine, Fuzhou 350122, China

CorrespondingAuthor:PAN Qunxiong Email: zijiansue@126.com

Abstract

Objective: To investigate the relationship between the preoperative platelet-to-lymphocyte ratio (PLR) and prognosis of hepatocellular carcinoma (HCC). Methods: The clinical data of 256 HCC patients undergoing surgical treatment were retrospectively analyzed. According to the preoperative PLR level of the patients, the receiver operating characteristic (ROC) curve was drawn, the cut-off value was determined, and the relations of the preoperative PLR level with the clinicopathologic factors and prognosis of the patients were analyzed. Results: The area under the curve of ROC of PLR for diagnosis of tumor recurrence was 0.625 (95% CI=0.544– 0.706), with a sensitivity of 0.53, specificity of 0.70, and cut-off value of 131.81. The preoperative PLR level was significantly associated with the clinicopathologic factors that included preoperative serum albumin level, Child-Pugh liver function classification, the presence or absence of ascites, vascular invasion, and TNM stage (all P<0.05). Cox hazards model analysis identified that TNM stage (HR=1.441, 95% CI=1.721–2.635, P<0.001) and PLR level (HR=1.737, 95% CI=1.317–2.291, P<0.001) were independent prognostic factors for HCC, and PLR level (HR=1.893, 95% CI=1.434–2.497, P<0.001) was independent prognostic factor for HCC recurrence. Survival analysis showed that the preoperative 1-, 3- and 5-year tumor-free survival rate in patients with low preoperative PLR level (81.2%, 52.3% and 29.6%) were significantly higher than those in patients with higher preoperative PLR level (62.4%, 32.2% and 11.6%). Conclusion: Preoperative PLR can be used as a prognostic marker for HCC patients, and those with high PLR level may have a high risk of recurrence and poor prognosis.
Keywords：